Thalidomide-O-amido-C6-NH2 (TFA)
Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA), a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker, can be used in the synthesis of PROTACs[1].
Product Specifications
CAS Number
[1950635-14-9]
Product Name Alternative
Cereblon Ligand-Linker Conjugates 11 (TFA) ; E3 Ligase Ligand-Linker Conjugates 25 (TFA)
UNSPSC
12352005
Hazard Statement
H301-H312-H361
Target
Apoptosis; Autophagy; E3 Ligase Ligand-Linker Conjugates
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; PROTAC
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/E3_Ligase_Ligand-Linker_Conjugates_25_Trifluoroacetate.html
Purity
99.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NCCCCCCN)COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O.O=C(O)C(F)(F)F
Molecular Formula
C23H27F3N4O8
Molecular Weight
544.48
Precautions
P264-P270-P280-P302+P352-P330-P362+P364-P405-P501
References & Citations
[1]Bradner J, et al. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses. WO 2017024318 A1
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Cereblon
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items